OncoMyx Therapeutics targets hematologic and solid tumors with unique oncolytic virus called myxoma (MYXV) and a novel patented systemic delivery approach. The myxoma program is the result of two decades of oncolytic virus research in the laboratory of Professor Grant McFadden. Myxoma is a pox virus that is highly immunostimulatory, and is non-pathogenic in any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. Programs are in development for both hematology (myeloma and AML) as well as solid tumors. Professor McFadden sequenced the myxoma virus genome in 1999, and since then has produced dozens of genetically engineered constructs, demonstrating its ability as an oncolytic agent across many tumors in preclinical cell and animal models.
Location: United States, Arizona, Phoenix
Employees: 11-50
Total raised: $75M
Founded date: 2018
Investors 4
| Date | Name | Website |
| 10.12.2021 | Lumira Ven... | lumiravent... |
| - | Korea Inve... | partners.k... |
| - | B Capital ... | b.capital/ |
| - | B Capital ... | bcapgroup.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.12.2021 | Series B | $50M | - |
| 06.06.2019 | Series A | $25M | Boehringer... |
Mentions in press and media 8
| Date | Title | Description | Source |
| 09.12.2021 | OncoMyx closes $50M Series B | OncoMyx Therapeutics has raised $50 million in a round co-led by Lumira Ventures and B Capital Group... | pitchbook.... |
| 08.12.2021 | OncoMyx nabs $50M to jump into the clinic with its rabbit po... | In April, startup OncoMyx published some very early preclinical models showing its engineered rabbit... | fiercebiot... |
| 08.12.2021 | OncoMyx nabs $50M to jump into the clinic with its rabbit po... | In April, startup OncoMyx published some very early preclinical models showing its engineered rabbit... | fiercebiot... |
| 08.12.2021 | OncoMyx Closes $50M Series B | PHOENIX, AZ, OncoMyx Therapeutics, a privately-held immuno-oncology platform company, announced th... | vcnewsdail... |
| 08.12.2021 | OncoMyx Closes $50 Million Series B to Advance a Novel Immun... | OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing... | marketscre... |
| 05.06.2019 | OncoMyx Therapeutics Completes $25M Series A | PHOENIX, AZ, Oncolytic immunotherapy company announced the completion of a $25 million series A fi... | vcnewsdail... |
| 05.06.2019 | OncoMyx Therapeutics Closes $25M Series A Financing | OncoMyx Therapeutics, a Phoenix, AZ-based oncolytic immunotherapy company, completed a $25m series A... | finsmes.co... |
| 05.06.2019 | OncoMyx Therapeutics Completes $25 Million Series A Financin... | PHOENIX–(BUSINESS WIRE)–June 5, 2019– OncoMyx Therapeutics, a privately-held oncolytic immunotherap... | venturebea... |